RxDoctor Payments DataLook up a doctor →

Mary Howell, MD

Internal Medicine · Hagerstown, MDNPI 1821058710

Payments from drug & device makers

$6,218,219in general payments, 2019–2025

Across 1,713 payments — averaging $3630.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2M
  • UCB SA$1.3M
  • Janssen Research & Development, LLC$880K
  • Gilead$651K
  • Eli Lilly$321K
  • Amgen$301K
  • plus $767K from 34 others
$12,071in research payments, 2019–2025

Across 5 payments — averaging $2414.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$12K
  • Gilead$84

What the payments were for

  • Travel & lodging$8629%
  • Food & beverage$8,66691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,218,219 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$1,346,752
Medicare patients
738
Services billed
91,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib13$108,605
Hydroxychloroquine Sulfate110$4,806
Colchicine26$3,351
MethotrexateMethotrexate Sodium97$2,591
Celecoxib16$1,025
Levocetirizine Dihydrochloride18$714
Armodafinil12$595
Prednisone60$553
Sulfasalazine13$425
Allopurinol44$373
Alendronate Sodium34$357
Leflunomide14$335
Duloxetine Hcl12$333
Calcitriol13$300
Meloxicam18$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$77,580$108,60513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →